WuXi ATU and GeneMedicine partner to develop oncolytic virus products
Category: #business  By Hrishikesh Kadam  Date: 2019-11-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

WuXi ATU and GeneMedicine partner to develop oncolytic virus products

Oncolytic viruses are an emerging class of immunotherapy agents that preferentially infect and destroy cancer cells. Leading biotechnology companies are focusing their attention on the development of oncolytic virus products.

WuXi ATU Co., Ltd., a wholly-owned subsidiary of Shanghai-based WuXi AppTec, has reportedly unveiled a strategic collaboration with South Korean gene therapy biotech firm GeneMedicine to develop and manufacture oncolytic virus products.

For the record, GeneMedicine develops oncolytic adenovirus platform technologies. The company has developed several pipelines in the clinical stage with a strategic focus on solid tumor, lung, metastatic liver, and pancreatic cancer. WuXi ATU primarily focuses on developing cell therapy products and gene vector-based R&D, production and other related services.

As per the deal, WuXi ATU will offer comprehensive process development and production support along with Investigational New Drug (IND) filing services for GeneMedicine’s upcoming line of oncolytic virus products.

This collaboration between WuXi ATU and GeneMedicine is apparently the first chemistry, manufacturing and controls (CMC) development and manufacturing contract authorized by the Oncolytic Virus contract development and manufacturing organization (CDMO) platform. WuXi ATU and GeneSail Biotech have been jointly running the platform since August.

WuXi ATU will use the Oncolytic Virus CDMO platform to extend overall process development, viral stock characterization, viral bank manufacturing, and cGMP commercial manufacturing services to accelerate the development, manufacturing and commercialization for key pipelines at GeneMedicine.

Also read: Google Cloud and Ascension to build data-driven healthcare solutions

WuXi ATU’s Oncolytic Virus CDMO platform is an integrated cell and gene therapy platform that covers the entire range of high-quality products that comply with global standards, stated GeneMedicine CEO Dr. Chae-Ok Yun, adding that the collaboration will enable the company to move its pipelines from the clinical stage to commercialization more efficiently.

WuXi ATU will make full use of its one-stop service platform, which covers the overall range of processes from development to commercialization, to enable global customers to speed up the development of gene therapy and bring more advanced treatment to patients worldwide, noted Dr. Shuyuan Yao, General Manager of WuXi ATU.

The strategic alliance evidently marks another crucial milestone for the Chinese pharmaceutical giant to provide CMC development and manufacturing of oncolytic virus products that comply with global standards. The two companies seemingly plan to enable global customers to bring advanced therapies to patients much faster.

 

Source credits: https://www.wuxiapptec.com/news/press-release/3685

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Hrishikesh Kadam    

Hrishikesh Kadam

A graduate in electronics and telecommunication engineering, Hrishikesh Kadam has always found writing fascinating. Driven by a never-ending passion for content creation combined with a bit of experience in writing personal blogs, Hrishikesh blends his technical knowl...

Read More

More News By Hrishikesh Kadam

Pure Storage takes over Portworx to support Kubernetes & containers
Pure Storage takes over Portworx to support Kubernetes & containers
By Hrishikesh Kadam

Storage as-a-service solutions provider, Pure Storage, has reportedly signed an agreement for the acquisition of leading Kubernetes data services platform, Portworx, for an approximate sum of $370 million. The transaction is reported to be the larges...

MaxLinear purchases intellectual property provider NanoSemi Inc
MaxLinear purchases intellectual property provider NanoSemi Inc
By Hrishikesh Kadam

Leading integrated circuits provider, MaxLinear, Inc., has reportedly announced its takeover of NanoSemi, Inc., the forerunner in the provision of intellectual property, deploying patented machine learning techniques for the enhancement of power effi...

Syncron introduces new solutions to enhance Syncron Service Cloud
Syncron introduces new solutions to enhance Syncron Service Cloud
By Hrishikesh Kadam

Syncron has recently announced two new releases to make significant enhancements to its Syncron Service Cloud. The Syncron Inventory 20.1 and Price 20.2 solutions are designed to assist OEMs (original equipment manufacturers) in enhancing their liqui...